Do we have drugs for dementia?: No

Archives of Neurology

Volumn 56, Issue 6, 1999, Pages 735-737

  Pryse Phillips, William ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; ALPHA TOCOPHEROL; ANIRACETAM; ARECOLINE; DIHYDROERGOTOXINE MESILATE; DONEPEZIL; GINKGO BILOBA EXTRACT; MEMANTINE; NALOXONE; NIMODIPINE; NOOTROPIC AGENT; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; PHYSOSTIGMINE; PROPENTOFYLLINE; SELEGILINE; TACRINE;

ALZHEIMER DISEASE; CAREGIVER; COGNITION; DAILY LIFE ACTIVITY; DEMENTIA; INSTITUTIONALIZATION; MEMORY; NOTE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RATING SCALE; SYMPTOMATOLOGY;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DEMENTIA; GINKGO BILOBA; HUMANS; INDANS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PHYTOTHERAPY; PIPERIDINES; PLANTS, MEDICINAL; SELEGILINE; TACRINE; VITAMIN E;

EID: 0032999743     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.6.735     Document Type: Note

References (37)

1. Chatellier G, Lacomblez L, for Groupe Français d'Etude de la Tetrahydroaminoacridine. Tacrine (tetrahydroaminoacridine, THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. BMJ. 1990;300:495-499.
2. Molloy DW, Guyatt GH, Wilson DB, et al. Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease. CMAJ. 1991;144:29-34.
3. Gracon SI. Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies. Acta Neurol Scand Suppl. 1996;165:114-122.
4. Knapp MJ, Knopman DS, Solomon PR, et al, for the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer disease. JAMA. 1994;271:985-991.
5. Raskind MA, Sadowsky CH, Sigmund WR, et al. Effect of tacrine on language, praxis, and non-cognitive behavioral problems in Alzheimer disease. Arch Neurol. 1997;54:836-840.
6. Knopman D, Schneider L, Davis K, et al, for the Tacrine Study Group. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology. 1996;47:166-177.
7. Wolfson C, Moride Y, Perrault A, et al. A Study of the Efficacy, Effectiveness and Economic Impact of Tacrine in Alzheimer's Disease. Ottawa, Ontario: Canadian Co-ordinating Office for Health Technology Assessment; June 1997.
8. Rogers SL, Friedhoff LT, for the Donezepil study group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter randomized, double-blind controlled clinical trial. Dementia. 1996;7:293-303.
9. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicenter open-label study. Eur Neuropsychopharmacol. 1998;8:67-75.
10. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind placebo-controlled trial of donezepil in patients with Alzheimer's disease. Neurology. 1998;50:136-145.
11. Gnemmi P, Rossi F, Monteverde A, et al. Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther. 1990;12:315-322.
12. Campi N, Todeschini GP, Scarzella L, et al. Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther. 1990;12: 306-314.
13. Lawlor BA, Aisen PS, Green C, et al. Selegiline in the treatment of behavioural disturbance in Alzheimer's disease. Int J Geriatr Psychiatry. 1997; 12:319-322.
14. Final G, Piccirilli M, Oliani C, et al. L-deprenyl therapy improves verbal memory in amnesic Alzheimer patients. Clin Neuropharmacol. 1991;14: 523-536.
15. Finali G, Piccirilli M, Oliani C, et al. Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy. Ital J Neurol Sci. 1992; 13:141-148.
16. Mangoni A, Grassi MP, Frattola L, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol. 1991;31:100-107.
17. Burke WJ, Roccaforte WH, Wengel SP, et al. L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc. 1993;41:1219-1225.
18. Sano M, Ernesto C, Thomas RG, et al, for the Alzheimer's Disease Cooperative Study: a controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997;336:1216-1222.
19. Kanowski S, Herrmann WM, Stephan K, et al. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry. 1996;29:47-56.
20. LeBars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF, for the North American EGb Study Group. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. JAMA. 1997;278:1327-1332.
21. Antuono PG, for the Mentane Study Group. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Arch Intern Med. 1995; 155:1766-1772.
22. Thai LJ, Schwartz G, Sano M, et al, for the Physostigmine Study Group: a multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology. 1996;47:1389-1395.
23. Thai LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitme in patients with Alzheimer's disease. Neurology. 1996;47:705-711.
24. Rai G, Wright G, Scott L, et al. Double-blind, placebo controlled study of acetyl-L-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin. 1990;11:638-647.
25. Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology. 1991;41:1726-1732.
26. Foster NL, Petersen RC, Gracon SI, et al, for the Tacrine 970-6 Study Group. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. Dementia. 1996;7:260-266.
27. Heyman A, Schmechel D, Wilkinson W, et al. Failure of long-term high-dose lecithin to retard progression of early-onset Alzheimer's disease. J Neural Transm Suppl. 1987;24:279-286.
28. Davidson M, Zemishlany Z, Mohs RC, et al. 4-Aminopyridine in the treatment of Alzheimer's disease. Biol Psychiatry. 1988;23:485-490.
29. Delwaide PJ, Gyselynck-Mambourg AM, Hurtet A, et al. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol Scand. 1986;73:136-140.
30. Fleischhacker WW, Buchgeher A, Schubert H. Memantine in the treatment of senile dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10:87-89.
31. Tariot PN, Cohen RM, Welkowitz JA, et al. Multiple-dose arecoline infusions in Alzheimer disease. Arch Gen Psychiatry. 1988;45:901-904.
32. Tariot PN, Sunderland T, Weingartner H, et al. Naloxone and Alzheimer disease: cognitive and behavioral effects of a range of doses. Arch Gen Psychiatry. 1986;43:727-732.
33. Rockwood K, Beattie BL, Eastwood MR, et al. A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. Can J Neurol Sci. 1997;24:140-145.
34. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry. 1990;27:1133-1142.
35. Senin U, Abate G, Fieschi C, et al. Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo-controlled multicentre clinical study. Eur Neuropsychopharmacol. 1991;1:511-517.
36. Marcusson J, Rother M, Kittner B, for the European Propentofylline Study Group. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dement Geriatr Cogn Disord. 1997;8:320-328.
37. van Reekum R, Black SE, Conn D, Clarke D. Cognition-enhancing drugs in dementia: a guide to the near future. Can J Psychiatry. 1997;42(suppl 1): 35S-50S.